The orally administered selective TRPV1 antagonist, JTS-653, attenuates chronic pain refractory to non-steroidal anti-inflammatory drugs in rats and mice including post-herpetic pain

Journal of Pharmacological Sciences

Volumn 122, Issue 2, 2013, Pages 128-137

  Kitagawa, Yoshihiro ^a   Tamai, Isao ^a   Hamada, Yuji ^a   Usui, Kenji ^a   Wada, Masashi ^a   Sakata, Masahiro ^a   Matsushita, Mutsuyoshi ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

Chronic pain; Herpes simplex virus 1 (HSV 1); Non steroidal anti inflammatory drug (NSAID); Post herpetic pain; Transient receptor potential vanilloid type 1 (TRPV1)

Indexed keywords

3 (HYDROXYMETHYL) 4 (5 METHYLPYRIDIN 2 YL) N [6 [2,2,2 TRIFLUOROETHOXY]PYRIDIN 3 YL] 3,4 DIHYDRO 2H BENZO[B][1,4]OXAZINE 8 CARBOXAMIDE; FORMALDEHYDE; FREUND ADJUVANT; GABAPENTIN; INDOMETACIN; JTS 653; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CHRONIC PAIN; DISEASE SEVERITY; EXPERIMENTAL MODEL; HERPES SIMPLEX VIRUS 1; HINDLIMB; HYPERALGESIA; INOCULATION; LUMBAR SPINE; MECHANICAL STIMULATION; MOTOR COORDINATION; MOUSE; NERVE LIGATION; NOCICEPTION; NOCICEPTIVE STIMULATION; NONHUMAN; POSTHERPETIC NEURALGIA; RAT; SINGLE DRUG DOSE; SPINAL NERVE; THERMAL STIMULATION;

EID: 84880797755     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.12276FP     Document Type: Article

References (43)

1. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287-333.
2. Abbadie C, McManus OB, Sun S-Y, Bugianesi RM, Dai G, Haedo RJ, et al. Analgesic effects of a substituted N-Triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker. J Pharmacol Exp Ther. 2010;334:545-555.
3. Nagakura Y, Okada M, Kohara A, Kiso T, Toya T, Iwai A, et al. Allodynia and hyperalgesia in adjuvant-induced arthritic rats: time course of progression and efficacy of analgesics. J Pharmacol Exp Ther. 2003;306:490-497.
4. Takasaki I, Andoh T, Shiraki K, Kuraishi Y. Allodynia and hyperalgesia induced by herpes simplex virus type-1 infection in mice. Pain. 2000;86:95-101.
5. Takasaki I, Sasaki A, Andoh T, Nojima H, Shiraki K, Kuraishi Y. Effects of analgesics on delayed postherpetic pain in mice. Anesthesiology. 2002;96:1168-1174.
6. Szallasi A, Cortright DN, Blum CA, Eid SR. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov. 2007;6:357-372.
7. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389:816-824.
8. Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron. 1998;21:531-543.
9. Moriyama T, Higashi T, Togashi K, Iida T, Segi E, Sugimoto Y, et al. Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain. 2005;1:3.
10. Tominaga M, Wada M, Masu M. Potentiation of capsaicin receptor activity by metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia. Proc Natl Acad Sci U S A. 2001;98:6951-6956.
11. Zhuang ZY, Xu H, Clapham DE, Ji RR. Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization. J Neurosci. 2004;24:8300-8309.
12. Puttfarcken PS, Han P, Joshi SK, Neelands TR, Gauvin DM, Baker SJ, et al. A-995662 [(R)-8-(4-methyl-5-(4-(trifluoromethyl) phenyl)oxazol-2-ylamino)-1,2, 3,4-tetrahydr onaphthalen-2-ol], a novel, selective TRPV1 receptor antagonist, reduces spinal release of glutamate and CGRP in a rat knee joint pain model. Pain. 2010;150:319-326.
13. Kanai Y, Nakazato E, Fujiuchi A, Hara T, Imai A. Involvement of an increased spinal TRPV1 sensitization through its up-regulation in mechanical allodynia of CCI rats. Neuropharmacol-ogy. 2005;49:977-984.
14. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10: 895-926.
15. Fukuoka T, Tokunaga A, Tachibana T, Dai Y, Yamanaka H, Noguchi K. VR1, but not P2X(3), increases in the spared L4 DRG in rats with L5 spinal nerve ligation. Pain. 2002;99: 111-120.
16. Luo H, Cheng J, Han JS, Wan Y. Change of vanilloid receptor 1 expression in dorsal root ganglion and spinal dorsal horn during inflammatory nociception induced by complete Freund's adjuvant in rats. Neuroreport. 2004;15:655-658.
17. Rashid MH, Inoue M, Bakoshi S, Ueda H. Increased expression of vanilloid receptor 1 on myelinated primary afferent neurons contributes to the antihyperalgesic effect of capsaicin cream in diabetic neuropathic pain in mice. J Pharmacol Exp Ther. 2003;306:709-717.
18. Pomonis JD, Harrison JE, Mark L, Bristol DR, Valenzano KJ, Walker K. N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl) tetrahydropyrazine-1(2H)- carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain. J Pharmacol Exp Ther. 2003;306: 387-393.
19. Watabiki T, Kiso T, Kuramochi T, Yonezawa K, Tsuji N, Kohara A, et al. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect. J Pharmacol Exp Ther. 2011;336: 743-750.
20. Honore P, Wismer CT, Mikusa J, Zhu CZ, Zhong C, Gauvin DM, et al. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J Pharmacol Exp Ther. 2005;314:410-421.
21. Joshi SK, Honore P, Hernandez G, Schmidt R, Gomtsyan A, Scanio M, et al. Additive antinociceptive effects of the selective Nav1.8 blocker A-803467 and selective TRPV1 antagonists in rat inflammatory and neuropathic pain models. J Pain. 2009; 10:306-315.
22. Kitagawa Y, Miyai A, Usui K, Hamada Y, Deai K, Wada M, et al. Pharmacological Characterization of (3S)-3-(Hydroxymethyl)-4-(5-Methylpyridin-2- yl)-N-[6-(2,2,2-Trifluoroethoxy)pyrid in-3-yl]-3,4-Dihydro-2H-Benzo[b][1,4] Oxazine-8-Carboxamide (JTS-653), a novel transient receptor potential vanilloid 1 antagonist. J Pharmacol Exp Ther. 2012;342:520-528.
23. Randall LO, Selitto JJ. A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther. 1957; 111:409-419.
24. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain. 1992;50:355-363.
25. Maher MP, Bhattacharya A, Ao H, Swanson N, Wu NT, Freedman J, et al. Characterization of 2-(2,6-dichloro-benzyl)-thiazolo[5,4-d]pyrimidin-7-yl]-(4- trifluoromethyl-phenyl)-amine (JNJ-39729209) as a novel TRPV1 antagonist. Eur J Pharmacol. 2011;663:40-50.
26. Beiche F, Scheuerer S, Brune K, Geisslinger G, Goppelt-Struebe M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett. 1996;390: 165-169.
27. Cui M, Honore P, Zhong C, Gauvin D, Mikusa J, Hernandez G, et al. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. J Neurosci. 2006;26: 9385-9393.
28. Abbadie C, Brown JL, Mantyh PW, Basbaum AI. Spinal cord substance P receptor immunoreactivity increases in both inflammatory and nerve injury models of persistent pain. Neuroscience. 1996;70:201-209.
29. Mapp PI, Terenghi G, Walsh DA, Chen ST, Cruwys SC, Garrett N, et al. Monoarthritis in the rat knee induces bilateral and time-dependent changes in substance P and calcitonin gene-related peptide immunoreactivity in the spinal cord. Neuroscience. 1993;57:1091-1096.
30. Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain. 2003;105:133-141.
31. Kuraishi Y, Takasaki I, Nojima H, Shiraki K, Takahata H. Effects of the suppression of acute herpetic pain by gabapentin and amitriptyline on the incidence of delayed postherpetic pain in mice. Life Sci. 2004;74:2619-2626.
32. Takasaki I, Andoh T, Nitta M, Takahata H, Nemoto H, Shiraki K, et al. Pharmacological and immunohistochemical characterization of a mouse model of acute herpetic pain. Jpn J Pharmacol. 2000;83:319-326.
33. Sasaki A, Takasaki I, Andoh T, Shiraki K, Takeshima H, Takahata H, et al. Nociceptin-receptor deficiency prevents postherpetic pain without effects on acute herpetic pain in mice. Neuroreport. 2008;19:83-86.
34. Sasaki A, Mabuchi T, Serizawa K, Takasaki I, Andoh T, Shiraki K, et al. Different roles of nitric oxide synthase-1 and -2 between herpetic and postherpetic allodynia in mice. Neuroscience. 2007;150:459-466.
35. Christoph T, Gillen C, Mika J, Grunweller A, Schafer MK, Schiene K, et al. Antinociceptive effect of antisense oligonucle-otides against the vanilloid receptor VR1/TRPV1. Neurochem Int. 2007;50:281-290.
36. Christoph T, Bahrenberg G, De Vry J, Englberger W, Erdmann VA, Frech M, et al. Investigation of TRPV1 loss-of-function phenotypes in transgenic shRNA expressing and knockout mice. Mol Cell. Neurosci. 2008;37:579-589.
37. Christoph T, Grunweller A, Mika J, Schafer MK, Wade EJ, Weihe E, et al. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochem Biophys Res Commun. 2006;350:238-243.
38. Dallel R, Raboisson P, Clavelou P, Saade M, Woda A. Evidence for a peripheral origin of the tonic nociceptive response to subcutaneous formalin. Pain. 1995;61:11-16.
39. Coderre TJ, Melzack R. The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury. J Neurosci. 1992;12:3665-3670.
40. Torres-Lopez JE, Ortiz MI, Castaneda-Hernandez G, Alonso-Lopez R, Asomoza-Espinosa R, Granados-Soto V. Comparison of the antinociceptive effect of celecoxib, diclofenac and resvera-trol in the formalin test. Life Sci. 2002;70:1669-1676.
41. Rowbotham MC, Nothaft W, Duan WR, Wang Y, Faltynek C, McGaraughty S, et al. Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial. Pain. 2011;152:1192-1200.
42. Gavva NR, Treanor JJ, Garami A, Fang L, Surapaneni S, Akrami A, et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain. 2008;136: 202-210.
43. Reilly RM, McDonald HA, Puttfarcken PS, Joshi SK, Lewis L, Pai M, et al. Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature. J Pharmacol Exp Ther. 2012;342:416-428.